OKYO Pharma Ltd

OKYO Nasdaq SEC CIK 1849296
Follow OKYO Pharma Weekly email: filings, results

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income6 fiscal years
−$20M−$15M−$10M−$5M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$4.7M
FY24−$16.8M
FY23−$13.3M
FY22−$5.4M
FY21−$3.4M
FY20−$1.5M
Free cash flowOperating cash flow minus capital expenditure
−$8M−$6M−$4M−$2M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$1.8M
FY24-
FY23−$7.7M
FY22−$5.5M
FY21−$1.6M
FY20-